AimedBio said second-quarter revenue rose 166% from a year earlier to 20.2 billion won, or about $14.2 million, as milestone payments from licensing and co-development agreements lifted earnings. First-half revenue reached 28.7 billion won, or about $20.2 million, while operating profit totaled 4.6 billion won, or about $3.2 million. The company said this marked a fourth consecutive half-year of operating profit, a streak it dated to the second half of 2024. The revenue gain was driven by progress in key antibody-drug conjugate pipelines, including ODS025, licensed to Boehringer Ingelheim, and AMB303, which is being co-developed with SK Plasma. AimedBio said ODS025, a lead candidate for multiple solid tumors, recently received U.S. Food and Drug Administration Investigational New Drug clearance for a Phase 1 trial and is slated for a global study at 13 institutions in five countries, including the United States and South Korea, with about 90 patients. Some reports have also described the program as having FDA clearance for a Phase 2 trial plan. AMB303 targets ROR1 across several solid tumors and is being advanced toward clinical entry this year. AimedBio said net assets including cash equivalents now exceed 200 billion won, or about $141.1 million, giving it room to increase self-run clinical development alongside its licensing strategy. The company said it aims to keep using upfront payments, R&D funding and milestone payments from partnerships to finance its own pipeline expansion.